{"entity":{"id":"legend-2","kind":"trial","name":"LEGEND-2","aka":[],"tldr":"The small Chinese trial whose startling response rates at ASCO 2017 drew Johnson and Johnson to Legend Biotech and became the myeloma CAR-T Carvykti.","summary":"57 patients treated at Xi'an Jiaotong University's Second Affiliated Hospital (Journal of Hematology and Oncology 2018): objective response 88%, complete response 68%, median progression-free survival 15 months, manageable cytokine release syndrome; a further 17 patients were treated at three other sites. Presented at ASCO 2017 by Fan Xiaohu and Zhao Wanhong, it led to the December 2017 Janssen collaboration ($350 million upfront) and to CARTITUDE-1, FDA approval as ciltacabtagene autoleucel in 2022 and NMPA approval in 2024. The clearest case of a Chinese academic-industry cell therapy becoming a global standard.","status":"positive","asOf":"2026-09-10","links":[{"label":"ClinicalTrials.gov NCT03090659","url":"https://clinicaltrials.gov/study/NCT03090659"},{"label":"J Hematol Oncol 2018","url":"https://doi.org/10.1186/s13045-018-0681-6"}],"tags":["china"],"related":["cartitude-1","cartitude-4"],"cancers":["multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":["bcma"],"drugs":["ciltacabtagene-autoleucel"],"companies":["legend-biotech","johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["zhang-fangliang"],"bottlenecks":[],"keyPapers":["paper-zhao-j-hematol-oncol"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03090659","phase":"1/2","setting":"Relapsed or refractory multiple myeloma, four hospitals in China: LCAR-B38M, a BCMA CAR-T with two llama-derived binding domains","sponsor":"Legend Biotech with Xi'an Jiaotong University and other Chinese hospitals","result":"ORR 88%, CR 68%, median PFS 15 months (Xi'an cohort, n = 57).","started":"2015-10-02","startedType":"actual","yearReported":2017,"enrolled":57,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective response rate","primary":true,"unit":"%","arms":[{"name":"LCAR-B38M","n":57,"value":88}],"source":"https://doi.org/10.1186/s13045-018-0681-6"}]},"route":"/trials/legend-2/","neighbours":{"trial":[{"id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/"},{"id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/"}],"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"drug":[{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"},{"id":"legend-biotech","kind":"company","name":"Legend Biotech","route":"/companies/legend-biotech/"}],"person":[{"id":"zhang-fangliang","kind":"person","name":"Fangliang (Frank) Zhang","route":"/people/zhang-fangliang/"}],"paper":[{"id":"paper-zhao-j-hematol-oncol","kind":"paper","name":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","route":"/key-papers/paper-zhao-j-hematol-oncol/"}]}}